NDC Compounded Drug 69194-138-01 Bupivacaine Hydrochloride; Lidocaine Hydrochloride

Injection, Solution Retrobulbar

Table of Contents

    1. Compounded Product Information
    2. NDC Crossover Products Matching 138 Bupivacaine Hcl 0.375%, Lidocaine Hcl 2% Syringe
    3. Frequently Asked Questions

Compounded Drug Product Information

NDC Product Code 69194-138
NDC Package Code 69194-138-01
11-Digit NDC Billing Format NDC Format for Billing
For insurance billing purposes the Centers for Medicare & Medicaid Services (CMS) created an 11 digit NDC derivative identifier. If the NDC Package code is less than 11 digits the code must be padded with leading zeros. The leading zeros must be added to the appropriate segment to create a 5-4-2 configuration.		 69194013801
Package Description 5 mL in 1 SYRINGE
Product Type What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.		 Human Compounded Drug
Proprietary Name What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.		 138 Bupivacaine Hcl 0.375%, Lidocaine Hcl 2% Syringe
Non-Proprietary Name What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.		 Bupivacaine Hcl, Lidocaine Hcl
Substance Name What is the Substance Name?
An active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.		 Bupivacaine Hydrochloride; Lidocaine Hydrochloride
Dosage Form Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Route Name Retrobulbar - Administration behind the pons or behind the eyeball.
Marketing Category OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
Labeler Code 69194
Labeler Name What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.		 Pine Pharmaceuticals Llc
Substance Name Bupivacaine Hydrochloride; Lidocaine Hydrochloride
Active Ingredients Information 3.75 mg/1 mL; 20 mg/1 mL
Reporting Period 2025-1

NDC Crossover Products Matching Bupivacaine Hydrochloride; Lidocaine Hydrochloride

NDC crossover of 138 Bupivacaine Hcl 0.375%, Lidocaine Hcl 2% Syringe with NDC 69194-138 a human compounded drug with other similar products matching the same substance name (Bupivacaine Hydrochloride; Lidocaine Hydrochloride) and the same administration route (retrobulbar) or dosage form (injection, solution).

Frequently Asked Questions

What is the NDC number assigned to 933 Bupivacaine Hcl 0.375%, Lidocaine Hcl 2% Syringe?

933 Bupivacaine Hcl 0.375%, Lidocaine Hcl 2% Syringe was assigned by its manufacturer with NDC product code 69194-138. This product is a drug classified as a human compounded drug. Compounded drugs are medications created by combining or altering existing drugs to meet the specific needs of certain patients. The NDC directory only includes information about compounded drugs from facilities that choose to assign NDC numbers to their products.

Which are the NDC package codes for 933 Bupivacaine Hcl 0.375%, Lidocaine Hcl 2% Syringe?

The NDC package code 69194-138-01 was assigned to a 5 mL in 1 SYRINGE of bupivacaine hydrochloride; lidocaine hydrochloride administered retrobulbar via injection, solution.

Who manufactures this product?

933 Bupivacaine Hcl 0.375%, Lidocaine Hcl 2% Syringe is manufactured by an outsourced facility and labeled by Pine Pharmaceuticals Llc. All compounded drugs included in the NDC directory are classified as "Outsourcing Facility Compounded Human Drug Product (Exempt from Approval Requirements)". Outsourcing facilities are a type of drug compounding facility regulated under Section 503B of the FD&C Act could be eligible for exemptions from drug registration if they meet all the conditions specified under Section 503B.

Which are the NDC crossover matchings for this product?

We found 2 matching products that have the same substance, dosage form and administration route. The matching products are manufactured by Pine Pharmaceuticals LLC with NDC product codes 69194-933-01 and 69194-933-01.